Fruquintinib-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Multiply Metastatic Rectal Cancer

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical colorectal cancer Pub Date : 2024-09-02 DOI:10.1016/j.clcc.2024.08.006

Caroline B. Ledet , Ugur Sener , Derek R. Johnson , Kimberly Ku , Thorvardur R. Halfdanarson

{"title":"Fruquintinib-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Multiply Metastatic Rectal Cancer","authors":"Caroline B. Ledet , Ugur Sener , Derek R. Johnson , Kimberly Ku , Thorvardur R. Halfdanarson","doi":"10.1016/j.clcc.2024.08.006","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Antiangiogenic agents are frequently used in the treatment of malignancies, such as colorectal cancer. Posterior reversible encephalopathy syndrome (PRES), a clinicoradiographic syndrome characterized by headache, encephalopathy, seizures, and characteristic magnetic resonance imaging (MRI) changes, is a rare but known complication of antiangiogenic therapies.</div></span></li><li><span>•</span><span><div>Fruquintinb is a tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF) receptors and has been recently approved for the treatment of colorectal cancer refractory to prior standard of care therapies. To date, only 1 other case of PRES associated with fruquintinib has been described. Our case highlights the possibility of PRES association with this novel antiangiogenic and emphasizes the importance of early recognition and management of this rare but potentially life-threatening treatment complication.</div></span></li><li><span>•</span><span><div>Our case underscores that prior tolerance of 1 antiangiogenic does not preclude occurrence of PRES associated with another agent from the same class.</div></span></li></ul></div></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"24 1","pages":"Pages 98-100"},"PeriodicalIF":3.3000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical colorectal cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1533002824000835","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

•
Antiangiogenic agents are frequently used in the treatment of malignancies, such as colorectal cancer. Posterior reversible encephalopathy syndrome (PRES), a clinicoradiographic syndrome characterized by headache, encephalopathy, seizures, and characteristic magnetic resonance imaging (MRI) changes, is a rare but known complication of antiangiogenic therapies.
•
Fruquintinb is a tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF) receptors and has been recently approved for the treatment of colorectal cancer refractory to prior standard of care therapies. To date, only 1 other case of PRES associated with fruquintinib has been described. Our case highlights the possibility of PRES association with this novel antiangiogenic and emphasizes the importance of early recognition and management of this rare but potentially life-threatening treatment complication.
•
Our case underscores that prior tolerance of 1 antiangiogenic does not preclude occurrence of PRES associated with another agent from the same class.

查看原文本刊更多论文

一名多发性转移性直肠癌患者的夫奎替尼相关后可逆性脑病综合征

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical colorectal cancer 医学-肿瘤学

CiteScore

5.50

自引率

2.90%

发文量

审稿时长

27 days

期刊介绍： Clinical Colorectal Cancer is a peer-reviewed, quarterly journal that publishes original articles describing various aspects of clinical and translational research of gastrointestinal cancers. Clinical Colorectal Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of colorectal, pancreatic, liver, and other gastrointestinal cancers. The main emphasis is on recent scientific developments in all areas related to gastrointestinal cancers. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.